During development, cells transition from a pluripotent to a differentiated state, generating all the different types of cells in the body. Development is generally considered an irreversible process, meaning that a differentiated cell is thought to be unable to return to the pluripotent state. However, it is now possible to reprogram mature cells to pluripotency. It is generally thought that reprogramming is accomplished by reversing the natural developmental differentiation process, suggesting that the two mechanisms are closely related. Therefore, a detailed study of cell reprogramming has the potential to shed light on unexplained developmental mechanisms and, conversely, a better understanding of developmental differentiation can help improve cell reprogramming. However, fundamental differences between reprogramming processes and multi-lineage specification during early embryonic development have also been uncovered. In addition, there are multiple routes by which differentiated cells can re-enter the pluripotent state. In this Review, we discuss the connections and disparities between differentiation and reprogramming, and assess the degree to which reprogramming can be considered as a simple reversal of development.
Introduction
More than 50 years ago, Conrad Waddington published his famous depiction of normal embryonic development, likening the process of differentiation to a ball rolling down a hill, from a pluripotent state to one of multiple differentiated states ( Fig. 1) (Waddington, 1957) . It has long been clear that the very early embryo must comprise cells with the potential to differentiate into all mature cell types in the body, and the idea has been that individual lineages gradually lose potency as they progress down their differentiation pathway (Fig. 2) . The isolation of mouse embryonic stem cells (ESCs) in the early 1980s (Evans and Kaufman, 1981; Martin, 1981) gave rise to a new scientific field devoted to understanding how these cells can be maintained in a pluripotent state or differentiated towards a particular cell type or tissue, and provided a highly accessible system in which Waddington's ideas could be explored.
However, as early as 1962, Sir John Gurdon reported the first definitive example of cellular reprogramming by cloning a frog through somatic cell nuclear transfer (injecting the nucleus from a differentiated intestinal epithelial cell into an enucleated oocyte, Fig. 3 ), making a significant dent into the model that differentiation is terminal. More recently, cellular reprogramming of differentiated mature cells into ESC-like cells called induced pluripotent stem cells (iPSCs) was achieved with the introduction of specific transcription factors (Fig. 3) (Takahashi and Yamanaka, 2006) and further challenged the unidirectionality of developmental differentiation. Returning to Waddington's landscape, this can be likened to the ball traveling upwards (Hochedlinger and Plath, 2009; Yamanaka, 2009 ) (see purple ball in Fig. 1 ). These findings raise several questions: to what extent and by which mechanisms is differentiation reversible and what are the implications of such reversal?
Here, we review the various types of pluripotency occurring both naturally in the embryo and in vitro through experimental manipulations. We then discuss the different biological processes occurring during cell reprogramming and their similarities with developmental programs. Finally, we examine whether the potency achieved by reprogramming differentiated cells into iPSCs is comparable to that seen in ESCs.
Pluripotency in vivo and in vitro
Developing embryos at the blastocyst stage give rise to two distinct cell types: the inner cell mass (ICM) and the trophoblast. The preimplantation embryo is composed of cells that each hold the inherited developmental capacity to generate all cell types in our body -including the germline − and that can contribute to all tissues of a chimeric mouse when transplanted into a host blastocyst. This broad developmental capacity is known as 'naïve' or 'ground state' pluripotency (Fig. 2) . Around implantation, the ICM segregates into a bilaminar embryonic disc composed of two distinct epithelial layers: the dorsal epiblast and ventral hypoblast. After implantation, epiblast cells show a more restricted potency and are thought to be unable to contribute to chimeras when injected into a host blastocyst (Nichols and Smith, 2012) . Subsequent gastrulation converts the bilaminar embryonic disc into three committed germ layers: ectoderm, mesoderm and endoderm (Fig. 2) .
In the mouse, self-renewing cells lines can be derived in vitro from the different lineages of the embryo at pre-and postimplantation stages: cells taken from the ICM can be propagated in a dish as ESCs (Evans and Kaufman, 1981; Martin, 1981; Bradley et al., 1984) , whereas cells taken from the post-implantation epiblast are cultured as EpiSCs (Brons et al., 2007; Tesar et al., 2007) . In general, these cell lines retain similar lineage potential to their in vivo source cells and hence exhibit different types of potency. Murine ESCs display a naïve pluripotency whereas EpiSCs are considered to be in a 'primed' pluripotent state because, although they are able to generate derivatives of the three germ layers in vitro, they rarely contribute to chimera formation in vivo (Fig. 2) . Human ESCs can also be derived from the ICM but, contrary to mouse ESCs, they spontaneously adopt a primed pluripotent state in vitro and exhibit properties including morphology, cytokine requirement and gene expression patterns that are reminiscent of murine EpiSCs .
Mouse ESC self-renewal can be maintained with a combination of cytokines, including bone morphogenetic protein (BMP) and leukemia inhibitory factor (LIF). However, ESCs constitute a heterogeneous population in vitro as a result of the fluctuating expression of several pluripotency markers such as Nanog, Klf4, Tbx3 and Rex1 (Ying et al., 2003; Niwa et al., 2009 ). This heterogeneity can be abolished by reversibly inhibiting cell differentiation using chemical inhibitors for mitogen-activated protein kinase (MEK) and glycogen synthase kinase 3 (GSK3) , resulting in a homogeneous population of naïve pluripotent stem cells. Exposure to such small molecules also allows the generation of germline-competent ESCs derived from nonpermissive mouse strains, such as non-obese diabetic (NOD) mice from which ESCs cannot easily be derived using standard culture methods (Hanna et al., 2009; ). Thus, naïve pluripotency can be stabilized and acquired in cells with different genetic backgrounds (Kawase et al., 1994; Ohtsuka and Niwa, 2015) . The nature of pluripotency is also variable across species. For example, similarly to mouse ESCs, rat ESCs exhibit and maintain naïve pluripotency under serum-free conditions with two kinase inhibitors (Buehr et al., 2008; Li et al., 2008) . By contrast, ESCs derived from rhesus monkey blastocysts exhibit primed pluripotency and do not contribute to chimeric animals (Thomson et al., 1995; Tachibana et al., 2012) . However, in some cases, the nature of the pluripotent state can be modulated. FAB-SCs, a mouse stem cell line established in a culture medium containing FGF and Activin, resembling the culture conditions used to derive primate ESCs, cannot contribute to chimeric mice or to teratoma formation, a hallmark of pluripotency (Chou et al., 2008) . However, the primed-like state of FAB-SCs can be reverted to a naïve state by exposing the cells to medium containing serum and LIF. Together, these observations suggest that species and culture conditions significantly affect the nature of pluripotency.
Several routes to pluripotency: mechanisms of cell reprogramming
The generation of pluripotent stem cell lines by cell reprogramming can be achieved using several methods such as somatic cell nuclear transfer (SCNT) into an enucleated egg (Wakayama et al., 2001) , fusion with a pluripotent stem cell (Tada et al., 2001 ), exposure to small chemical compounds (Hou et al., 2013) , and transduction of reprogramming factors (Takahashi and Yamanaka, 2006) (Fig. 3) . This latter technique for inducing pluripotency has also been used to convert a somatic cell directly into a different lineage, without inducing a stable pluripotent state (green and pink balls in Fig. 1 ), a process known as 'direct reprogramming' and reviewed extensively elsewhere (Zhou et al., 2008; Ieda et al., 2010; Vierbuchen et al., 2010; Huang et al., 2011; Sekiya and Suzuki, 2011) .
In the cases of SCNT-and cell fusion-mediated reprogramming, somatic cell nuclei are suddenly exposed to toti-or pluripotent environments. Consequently, these reprogramming methods are rapid (Tada et al., 2001; Egli et al., 2011) (Fig. 3) . By contrast, the transduction of the reprogramming factors POU domain class 5 transcription factor 1 (POU5F1, also known as OCT3/4), SRY (sex determining region Y)-box 2 (SOX2), Krüppel-like factor 4 (KLF4) and Myelocytomatosis oncogene (c-MYC) (together referred to as OSKM) results in a relatively slow reprogramming, presumably because the somatic cell nuclei are not immediately exposed to the cytoplasm of a pluripotent cell (Takahashi and Yamanaka, 2006) . Consequently, reprogramming somatic cells to pluripotency using exogenous factors, such as OSKM or a cocktail of chemical compounds (Hou et al., 2013) developmental intermediates. These differences in the kinetics of reprogramming suggest that the cytoplasmic memories of pluripotency, such as transcripts found in the egg or in pluripotent stem cells, are key for a fast reprogramming process.
Another key difference between the different reprogramming techniques cited above is their efficiency, which is very low in the case of the transduction of reprogramming factors, where only a small minority of cells is successfully reprogrammed (Fig. 3) . Such low efficacy can be explained by a stochastic model (Yamanaka, 2009) : most cells initiate the reprogramming process but only a few are able to complete it. One of the first events required for a successful reprogramming is the pioneer activity of the OSKM factors. Soufi et al. mapped the binding sites of OSKM on the human genome in the initial phase of the reprogramming of fibroblasts to iPSCs (Soufi et al., 2012) and found that c-Myc facilitates the engagement of OSK with chromatin and their binding to the enhancer regions of genes that promote reprogramming. Additionally, histone H3 lysine 9 trimethylation, a mark of repressive chromatin, was found at many of the pluripotency loci, impeding OSKM accessibility and thus reducing reprogramming efficiency.
Another factor that determines the success rate of reprogramming is the stoichiometry of the reprogramming factors. For example, iPSC-derived secondary fibroblasts carrying doxycycline-inducible OSKM expression cassettes, which achieve a uniform expression of OSKM at levels required for iPSC generation, can be efficiently reprogrammed to pluripotency (Wernig et al., 2008) . Additionally, it has been observed that reprogramming efficiency is enhanced by increasing levels of OCT3/4 and KLF4 (Papapetrou et al., 2009; Tiemann et al., 2011) as well as by lowering SOX2 expression (Yamaguchi et al., 2010) . It has also been shown that in the early phase of reprogramming towards pluripotency, OCT3/4 and SOX2 promote the expression of mesendodermal and neuroectodermal genes, respectively (Shu et al., 2013) , whereas KLF4 can induce the expression of epidermal genes in a context-dependent manner (Kim et al., 2015) . Thus, unbalanced OSKM expression deviates the intermediate cells from the reprogramming path. Consequently, these cells are unable to ever become iPSCs (Polo et al., 2012; Tanabe et al., 2013) . In addition to driving the reprogramming process, each of the OSKM factors has important developmental functions aside from promoting pluripotency (Payne et al., 1982; Nichols et al., 1998; Avilion et al., 2003; Jiang et al., 2008) , which could be favored if OSKM stoichiometry is not optimal, and could thus have an inhibitory influence on reprogramming. Therefore, well-balanced expression of reprogramming factors leads the somatic cells toward pluripotency.
During embryonic development, an undifferentiated cell must choose between multiple fates, whereas in reprogramming to pluripotency, there is a single end point (the iPSC) but multiple possible starting states. Can the suppression of somatic gene expression and activation of pluripotency genes during reprogramming be likened to the reversal of the loss of pluripotency that leads to the commitment of a pluripotent cell to a specialized lineage during embryogenesis? Below, we discuss some processes shared by developmental maturation and reprogramming.
Transition between mesenchymal and epithelial fates during differentiation and reprogramming During gastrulation, initiated by the formation of the primitive streak from the epiblast in mouse, pluripotent epiblast cells give rise to a structure with three committed germ layers (endoderm, mesoderm and ectoderm) (Tam and Loebel, 2007) (Fig. 2) . The primitive streak constitutes a gate through which cells migrate from the epiblast into the interior of the embryo via an epithelial-tomesenchymal transition (EMT) (Thiery et al., 2009; Chen et al., 2012) . Therefore, the morphological process of EMT is coupled with the first cell fate decision -the generation of three germ layersof the embryo.
Intriguingly, whereas EMT is thought to be important for cells to differentiate, the opposite process, mesenchymal-to-epithelial transition (MET), has been proposed as a requirement for the early phases of reprogramming Samavarchi-Tehrani et al., 2010) (Fig. 4) . Indeed, following OSKM transduction in fibroblasts, the expression of mesenchyme-related transcription factors, such as Snai1, Snai2, Twist1, Twist2, Zeb1 and Zeb2, are repressed both in mouse and human cells (Samavarchi-Tehrani et al., 2010; Takahashi et al., 2014) . At the same time, mesenchymal-specific surface proteins, Thy1 and Cd44, are repressed (O'Malley et al., 2013) . Epithelial features, such as the expression of E-cadherin (Cdh1), arise almost as soon as mesenchymal identity is lost. These changes occur prior to the expression of Stage specific embryonic antigen 1 (SSEA-1, also known as Fut4) an early phase marker of intermediate reprogrammed cells in mouse. Additionally, inhibition of MET by transforming growth factor-beta (TGFβ) treatment or forced expression of Snai1 prevents the formation of cell-cell junctions and drastically decreases the reprogramming efficiency (Ichida et al., 2009; Maherali and Hochedlinger, 2009) . Conversely, the inhibition of TGFβ signaling by using a TGFβ1 receptor inhibitor or the ectopic expression of Smad7, an antagonistic molecule of the TGFβ pathway, facilitates mouse iPSC generation. Bone morphogenic protein 4 (Bmp4), which also inhibits TGFβ signaling, also increases the efficiency of mouse iPSC generation. In addition, Bmp4 can functionally replace Klf4 to achieve reprogramming by enhancing MET . Interestingly, the transduction of Klf4 alone is sufficient for the induction of Cdh1 expression in the early phases of reprogramming of mouse embryonic fibroblasts (MEFs) to pluripotency Samavarchi-Tehrani et al., 2010) . Furthermore, forced expression of Klf4 can convert EpiSCs to the naïve state of pluripotency ). In addition, ectopic expression of Cdh1 in EpiSCs restores their capacity to contribute to normal development after blastocyst injection (Ohtsuka et al., 2012) . Therefore, the Klf4/Cdh1 axis is crucial for the acquisition of mouse naïve pluripotency. This suggests that, when the reprogramming process is activated, cells transit directly from a somatic to a postgastrulation-like stage, thereby bypassing the progenitor stage usually seen in the developmental path in vivo. In summary, during development, EMT is coupled to lineage specification whereas promoting MET increases reprogramming efficiency. In this way, MET and EMT are defining processes for the entrance or exit of pluripotency, respectively.
miRNA circuits regulate reprogramming and development
Most miRNAs function as post-transcriptional repressors by annealing to target messenger RNAs. Therefore, miRNAs complement transcription factors to regulate gene expression networks during cell fate changes. Indeed, the inhibition of miRNA biogenesis by targeted disruption of Dicer, a ribonuclease that cleaves double-stranded RNAs and pre-miRNAs into short double-stranded RNA fragments, impaired normal embryonic development and reduced the differentiation potential of ESCs (Kanellopoulou et al., 2005) . Interestingly, Dicer is also indispensable for the generation of iPSCs from MEFs (Kim et al., 2012) . In this way, miRNAs are crucial for cell fate changes both during development and reprogramming. Here, we discuss three key examples of miRNAs and associated proteins involved in the regulation of pluripotency: let-7, miR-290/295 and miR-302/367.
The LIN28/let-7/TRM71 axis
The let-7 family is abundantly expressed in somatic cells, but not in pluripotent cells and promotes terminal differentiation during development (Ambros, 2011). In the mouse embryo, let-7 expression starts at embryonic day (E) 8.5 (mid-gastrulation) and remains elevated through the newborn stages (Schulman et al., 2005) . Conversely, the levels of let-7 miRNA progressively decrease during reprogramming to iPSCs in mouse and human (Melton et al., 2010; Worringer et al., 2013) . LIN28, a factor that regulates stem cell renewal, inhibits the biogenesis of let-7 during mouse embryogenesis and in pluripotent stem cell lines (Heo et al., 2008 (Heo et al., , 2009 Viswanathan et al., 2008; West et al., 2009; Viswanathan and Daley, 2010) and improves the reprogramming efficiency of mouse and human cells (Yu et al., 2007; Yusa et al., 2009; Tanabe et al., 2013) . The same pattern is observed for a target of let-7, TRIM71 (Worringer et al., 2013) . TRIM71 is expressed in epiblasts and embryonic ectoderm by E9.5 and its expression pattern is the opposite to that of let-7 (Rybak et al., 2009 ). TRIM71 and let-7 functionally repress each other in a negative feedback loop. In fact, forced expression of the gene encoding TRIM71 along with OSK or OSKM facilitates iPSC generation and cancels out the negative effects of let-7 on reprogramming (Worringer et al., 2013) . During embryonic development, LIN28 plays important roles in primordial germ cell specification (West et al., 2009 ). In the embryo from E8.5 to E10.5, LIN28 expression is reduced and results in global let-7 activation. Trim71 knockout mouse embryos show abnormalities at E9.5 and die as a result of neural tube closure defects (Maller Schulman et al., 2008) . In mouse ESCs, TRIM71 is dispensable for self-renewal but its loss led to upregulation of genes required for neural development (Mitschka et al., 2015) suggesting that TRIM71 is associated with the priming of neural differentiation rather than with pluripotency. Thus, the activation of the LIN28/let-7/TRIM71 axis is important for early development whereas its repression is crucial for successful reprogramming. During embryonic development, a fertilized, pluripotent egg gives rise to a complete organism through cell differentiation. Conversely, the reprogramming process rejuvenates a mature cell and brings it to a pluripotent state. These two mechanisms share common events including changes in the expression of pluripotency and somatic genes, transitions between mesenchymal and epithelial states (through a mesenchymal-to-epithelial transition, MET, or an epithelial-to-mesenchymal transition, EMT), transient developmental genes expression, changes in telomere length, variations in X-chromosome activity, and evolution of the global DNA methylation status.
promoters and found that miR-290 was expressed in pluripotent cells from E3.5 to E6.5 (Parchem et al., 2014) . By E7.5 (gastrulation) and at later stages, miR-290 was expressed in extra-embryonic tissues but not in the epiblast. By contrast, the expression of miR-302 started from E5.5, just after implantation, and continued until the gastrulation stage. Finally, the expression of miR290 and miR302 is attenuated after gastrulation, when let-7 begins to be expressed. The analysis of such reporter systems also demonstrated specific expression of miR-290 in naïve ESCs and of miR-302 in primed EpiSCs. The miR-290/295 cluster plays important roles in embryonic development as knockout mouse embryos exhibit partially penetrant lethality (Medeiros et al., 2011) . In addition, knockout adult female mice show infertility as a result of premature ovarian failure (Medeiros et al., 2011) . The miR-302/367 cluster is a target of the transcription factor GATA binding protein (Gata) 6 in the lung and assumes key roles in proliferation and differentiation of lung endoderm progenitors (Tian et al., 2011) . In ESCs, these miRNA clusters both inhibit BMP/TGFβ-dependent EMT by repressing the translation of TGFβ receptor II (TgfbrII) and promote rapid ESC proliferation by accelerating the G1 to S transition via control of p21CIP1 (Cdkn1a) and cyclin D expression (Wang et al., 2008; Subramanyam et al., 2011) .
Interestingly, the analysis of transcription activator-like effector nuclease (TALEN)-mediated knockout cells revealed that the miR-302/367 cluster is crucial for iPSC generation from human cells . Furthermore, ectopic expression of OSK stochastically produced intermediates that express either or both miR-290 and miR-302 during reprogramming. These random patterns are very different from the patterns seen in early embryogenesis. Of note, the addition of Sal-like 4 (Sall4), a pluripotency-associated transcription factor, to OSK drastically increased the number of miR-290 − miR-302 + intermediate reprogrammed cells, akin to epiblast cells between E5.5 and gastrulation, and iPSC colony formation. These observations suggest that there are high heterogeneities in the intermediate reprogrammed cells induced by OSK, and that the intermediates such as miR-290 − miR-302 + cells that mimic the reversion of development preferentially become iPSCs. Additional factors, including Sall4, can help homogenize the intermediate state and facilitate the reprogramming efficiency. Taken together, these data suggest that the reversal of early embryonic miRNA circuits is an effective way to reprogram a cell to pluripotency.
Transient expression of developmental genes during reprogramming
During the reprogramming of somatic cells to pluripotency, somatic genes should be suppressed and pluripotency-associated genes upregulated. However, intermediates on the way to reprogramming can be identified, suggesting that a transient reprogrammed state might exist. It is possible that such a state reflects transient developmental intermediates, which can display a unique gene expression signature (such as, for example, the expression of the key mesoderm transcription factor T, also known as Brachyury, which defines mesoderm during gastrulation but is then downregulated; Marcellini et al., 2003) .
Several types of reporter lines carrying fluorescent proteins driven by the promoters of pluripotency genes, such as Oct3/4 and Nanog, have been established to distinguish cells undergoing reprogramming from those that are not (Maherali et al., 2007; Okita et al., 2007; Wernig et al., 2007; Park et al., 2008) . However, these reporter genes are activated at the late phase of the reprogramming process. To capture intermediates at the early phase of the process, cells can be labeled with antibodies against surface antigens such as SSEA-1 in mice and Tumor-related antigen-1-60 (TRA-1-60) in humans, facilitating the sorting and purification of cells at early stages of reprogramming (Buganim et al., 2012; Polo et al., 2012; O'Malley et al., 2013; Tanabe et al., 2013) . Thus, by removing nonreprogrammed cells early during the re-acquisition of pluripotency, researchers can also remove the associated noise, which improves study of the molecular events of reprogramming.
Although SSEA-1 is expressed at the early phase of reprogramming, its expression is sustained throughout the entire process. The analysis of SSEA-1 + intermediates derived from MEFs in the late phase of reprogramming showed transient expression of miR-302a, which is normally expressed in mouse EpiSCs and in the post-implantation epiblast but not in ESCs (Polo et al., 2012) . These data suggest that during reprogramming, cells transition through a primed epiblast-like state to reach a naïve pluripotent state. SSEA-1 + cells have also been shown to express mesendodermal markers such as Forkhead box A2 (FoxA2), Mix1 homeobox-like 1 (Mixl1) and Eomesodermin homolog (Eomes) but not ectodermal genes, suggesting that reprogramming takes them through a fate resembling the primitive streak, which is mainly composed of mesendodermal cells in embryos (Polo et al., 2012) .
During the reprogramming of human somatic cells towards iPSCs, TRA-1-60 + intermediates exhibit transient expression of mesendodermal but not ectodermal genes (Takahashi et al., 2014) . Additionally, a recent study has shown that ∼40% of 3771 human endogenous retroviruses type-H (HERV-Hs) transcripts, which are detected in both human pluripotent stem cells and mesendodermal cells, are transiently hyper-activated during reprogramming (Friedli et al., 2014; Lu et al., 2014; Ohnuki et al., 2014; Wang et al., 2014) . Furthermore, human ESCs and iPSCs expressing aberrantly high levels of HERV-H transcripts show defective directed differentiation down the neural lineage (Koyanagi-Aoi et al., 2013; Ohnuki et al., 2014) . A more recent study observed a transient signature reminiscent of pre-implantation stages marked by the expression of UTF1, DPPA3 and miR-371 during reprogramming even in human cells (Cacchiarelli et al., 2015) . Taken together, these data suggest that both mouse and human intermediate reprogrammed cells go through mesendodermal and epiblast-like states. However, MEF-derived SSEA-1 + intermediates also transiently express several genes associated with the epidermis, a much more specialized tissue derived from the ectoderm, suggesting that reprogramming is not a simple reversal of the normal developmental process (O'Malley et al., 2013; Kim et al., 2015) . Such transient expression of developmental genes in intermediate reprogrammed cells is thought to be directly or indirectly regulated by reprogramming factors. Recently, the roles of each reprogramming factor during the re-acquisition of pluripotency have been investigated. During reprogramming, OCT3/4 enhances the expression of mesendodermal genes and inhibits that of ectodermal genes (Montserrat et al., 2013; Shu et al., 2013) . SOX2 shows the opposite effect, as it correlates with an upregulation of ectodermal genes and a downregulation of mesendodermal genes (Montserrat et al., 2013; Shu et al., 2013) .
In the native primitive streak of mouse embryos high levels of Oct3/4 and low levels of Sox2 were observed around E7.5 (Teo et al., 2011) . In addition, in differentiating human ESCs OCT3/4 contributes to BMP-induced specification of a primitive streak-like state (Wang et al., 2012) , whereas SOX2 -again showing an opposite effect -represses this process (Wang et al., 2012) .
Furthermore, conditional loss-of-function experiments revealed that Oct3/4 is required for normal primitive streak development in gastrulating mouse embryos (DeVeale et al., 2013) . In the late phase of reprogramming, which proceeds independently of exogenous reprogramming factor expression, the expression of endogenous OCT3/4 reaches a level similar to that of ESCs and iPSCs. By contrast, the expression of endogenous SOX2, a late reprogramming marker in both mouse and human, slowly increases (Buganim et al., 2012; Takahashi et al., 2014) . These different timings of expression create an OCT3/4 high SOX2 low transition state and probably result in a primitive streak-like state characterized by high mesendodermal and low ectodermal gene expression.
The activation of endogenous SOX2 is the final piece of the reconstitution of the pluripotency transcription factor network during reprogramming (Buganim et al., 2012) . Furthermore, the high levels of OCT3/4 and SOX2 contribute to the maintenance of pluripotency not only in ESCs and iPSCs, but also in the ICM and the epiblast in blastocysts. In this way, reprogramming factors regulate lineage-specifying factors and induce the activation of other developmental genes during reprogramming. Taken together, these findings suggest that OCT3/4 and SOX2 regulate the expression of other developmental genes both during differentiation and reprogramming.
Intriguingly, OCT3/4 and SOX2 can be replaced with a cocktail of lineage specifiers, including GATA binding protein 3 (GATA3) and zinc finger protein 521 (ZFP521), to achieve cell reprogramming (Montserrat et al., 2013; Shu et al., 2013) , suggesting that these non-pioneer factors can promote dedifferentiation in the early phase of reprogramming.
Altogether, this body of work shows that, during reprogramming, OSKM factors not only induce pluripotency genes but also regulate the expression of lineage specifiers required during development. This suggests that cell differentiation and reacquisition of pluripotency might proceed through similar genetic programs and that reprogramming factors are not devoted to the establishment and maintenance of pluripotency but also play a role in cell differentiation. Equally, lineage specifiers can contribute to the reprogramming process.
In and out of pluripotency: epigenetic regulation
The epigenetic marks acquired during lineage commitment constitute one of the barriers separating cells in Waddington's landscape (Waddington, 1957) (Fig. 1) . Indeed, recent genomewide studies have uncovered crucial differences between the epigenetic landscape of lineage-committed cells and that of pluripotent cells, suggesting that the exit from and the re-entry to the pluripotent state is under epigenetic control.
DNA methylation
DNA methylation is an important epigenetic mark that regulates gene expression and genome stability. In mammals, two de novo DNA methyltransferases (Dnmt), 3a and 3b, are conserved. Double knockout of these two genes disrupted de novo DNA methylation in ESCs and led to smaller embryos with abnormal morphology at E8.5 and E9.5 and death before E11.5 (Okano et al., 1999) . However, Dnmt3a/3b are dispensable for mouse iPSC generation (Pawlak and Jaenisch, 2011) , even if ESCs lacking Dnmt3a/3b and iPSCs derived from Dnmt3a/3b knockout MEFs exhibit poor differentiation phenotypes (Chen et al., 2003; Pawlak and Jaenisch, 2011) . These data suggest that de novo DNA methylation is essential for cellular differentiation during normal embryonic development, but not for reprogramming.
DNA demethylation is mediated by the family of tet methylcytosine dioxygenase (Tet) enzymes (Tet1, 2 and 3) which catalyze the conversion of 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC), 5-hmC to 5-fC (5-formylcytosine), and 5-fC to 5-caC (5-carboxylcytosine). Tet1-deficient ESCs have reduced levels of 5-hmC and global gene expression changes (Dawlaty et al., 2011) . Nevertheless, these mutant cells contributed to the development of live-born pups in tetraploid complementation experiments, suggesting that they were pluripotent. By contrast, knockdown of Tet1 caused the downregulation of Nanog expression and LIF/Stat3 activity, and impaired mouse ESCs selfrenewal (Ito et al., 2010; Freudenberg et al., 2011) . Tet1 knockout mice are viable, fertile and grossly normal, though some have a slightly smaller body size at birth. Tet1/2 double knockout mice are also viable and fertile, but show lower 5-hmC and higher 5-mC levels and aberrant methylation statuses at various imprinted loci (Dawlaty et al., 2013) . Depletion of all Tet enzymes in ESCs caused loss of 5-hmC and impaired ESC differentiation (Dawlaty et al., 2014 ). These results demonstrate that Tet-mediated 5-hmC maintenance and DNA demethylation is crucial for the differentiation of ESCs and embryonic development.
Another component of the active DNA demethylation machinery, the DNA repair enzyme thymine DNA glycosylase (Tdg), is essential for normal mouse embryonic development (Cortázar et al., 2011; Cortellino et al., 2011) . By using Tet1/2 or Tdg-deficient MEFs, Hu et al. showed that the Tet/Tdg axis is essential for mouse iPSC generation : in the absence of these enzymes, the expression of miR-200, crucial for MET, is not induced as a result of insufficient demethylation of its promoter. Forced expression of miR-200 restores efficient reprogramming in knockout MEFs. Importantly, after the blockage of the MET step is overcome by the reintroduction of miR-200, Tet1/2 and Tdg were found to be dispensable for the activation of pluripotency genes such as Oct3/4. Thus, the role of DNA methylation appears to differ between development and reprogramming but active DNA demethylation is required for both cell fate changes. Taken together, the roles of DNA methylation and demethylation during reprogramming share more common ground with pluripotent stem cell lines than with early embryogenesis.
X-chromosome activity
In female mammalian somatic cells, X-chromosome inactivation (XCI) ensures gene dosage compensation, which normalizes the expression of genes on the X chromosome to that observed in male cells. During mouse embryonic development, there are two waves of XCI: paternal XCI and random XCI. Shortly after fertilization, the paternal X chromosome is silenced. This inactivation continues in extra-embryonic tissues, but is erased in the ICM (Mak et al., 2004; Okamoto et al., 2004) (Fig. 4) . Subsequently, random inactivation of either the maternal or paternal X-chromosome occurs. Therefore, all somatic cells derived from the ICM have a randomly inactivated X-chromosome (Xi). The non-coding X-inactivation specific transcript (Xist) plays an important role in triggering random chromosome-wide silencing (Brockdorff et al., 1991; Brown et al., 1991) . Xist is transcribed only from the Xi in somatic cells, and its monoallelic expression is highly correlated with the onset of XCI in female development and female ESC differentiation in mouse (Penny et al., 1996; Marahrens et al., 1997) .
The randomly inactivated X-chromosome in female somatic cells can be reactivated during transcription factor-mediated reprogramming (Maherali et al., 2007) . A recent study dissected the kinetics of X-chromosome reactivation during the reprogramming of MEFs (Pasque et al., 2014) . After the transduction of reprogramming factors into MEFs, the Xi colocalizes with EZH2, an enzyme of the Polycomb-group family that leads to chromatin condensation by the addition of three methyl groups to lysine 27 of histone 3 (H3K27me3). During the later phase of reprogramming, Xist is silenced and the localization of EZH2 to Xi is lost. At this point, late reprogramming markers such as Rex1 and Dppa4 start to be expressed, immediately followed by the biallelic expression of X-linked genes. Silencing of Xist is necessary but not sufficient for this process, which also requires DNA demethylation of the inactivated X-chromosome. The high persistence of DNA methylations that inactivate the X-chromosome during reprogramming in mouse might partly explain why a substantial time for X-chromosome reactivation is needed.
Interestingly, Tchieu et al. argued that reactivation of the X chromosome does not occur in human iPSCs (Tchieu et al., 2010) . Conversely, Tomoda et al. demonstrated that X-chromosome reactivation can occur in human iPSCs by extending the time of post-reprogramming culture and using SNL feeder cells that overexpress LIF (Tomoda et al., 2012) . Thus, the Xi found during embryogenesis can be gradually reactivated over time by cell reprogramming (Fig. 4) .
Telomere elongation during development and reprogramming
Embryonic pluripotent cells initially have long telomeres, conserved repetitive TTAGGG sequences at each end of the chromatids that protect the chromosome from degradation and fusion with other chromosomes (O'Sullivan and Karlseder, 2010) . These progressively shorten with each cell division and are associated with replicative senescence. Telomerase, a ribonucleoprotein polymerase, maintains the telomere ends, therefore playing a crucial role in cellular senescence. Its expression is normally silenced during differentiation, as a consequence of which telomeres progressively shorten with each cell division (Blasco, 2005) (Fig. 4) . Furthermore, telomerase dysregulation in somatic cells can contribute to oncogenesis (Collins, 2006) . Therefore, telomere shortening is associated with cellular senescence and constitutes a fundamental step in the developmental process.
Telomerase-dependent telomere elongation occurs after reprogramming of MEF-derived iPSCs and continues until a telomere length similar to that in ESCs is reached (Marion et al., 2009b) (Fig. 4) . However, it was demonstrated that telomere elongation is dispensable for mouse iPSC generation (Tejera et al., 2010; Kinoshita et al., 2014) . Interestingly, MEFs derived from third generation (G3) Telomerase RNA component (Terc) knockout mice showed significantly low reprogramming efficiency and massive apoptosis. Furthermore, this diminished efficiency could be rescued by reintroduction of telomerase or suppression of p53 (Trp53), suggesting that increased DNA damage induced by the short telomeres reduced iPSC generation efficiency (Marión et al., 2009a) . Accordingly, reducing the DNA damage response significantly facilitated reprogramming toward iPSCs (Banito et al., 2009; Hong et al., 2009; Kawamura et al., 2009; Li et al., 2009; Marión et al., 2009a; Utikal et al., 2009) . In Terc knockout mice, shortened telomeres exhibit a DNA damage response that is followed by chromosomal fusions, aneuploidy and apoptosis (Blasco et al., 1997; Rajaraman et al., 2007) . Similarly to its role during development, telomerase activity contributes to cell maturation: iPSCs derived from G3 Terc knockout tail-tip fibroblasts (TTFs) had low differentiation potential and showed neither a contribution to chimeric mice nor teratoma formation activity . These G3 Terc −/− iPSCs also exhibited senescence-associated phenotypes, including the elevation of p21CIP1 expression, mitochondrial dysfunction and telomere shortening. Furthermore, restoring mitochondria function by ectopic expression of PGC-1α (also known as PPARGC1A) increased their differentiation potential. Taken together, countering DNA damage by telomere elongation promotes early development and reprogramming.
Comparing iPSCs and ESCs
The above sections discuss some of the commonalities between reprogramming and embryonic development. In this section, we consider the debate on whether iPSCs and ESCs are equivalent cell types generated by different methods.
Dozens of reports have claimed that, despite the fact that they both share pluripotency, iPSCs differ from ESCs by their epigenetic relics of somatic origin, including DNA methylation and gene expression (Chin et al., 2009; Deng et al., 2009; Doi et al., 2009; Marchetto et al., 2009; Ghosh et al., 2010; Kim et al., 2011; Lister et al., 2011; Ohi et al., 2011) . However, many others have demonstrated that there are no differences between ESCs and iPSCs, including their somatic epigenetic memory (Guenther et al., 2010; Newman and Cooper, 2010; Bock et al., 2011; Rouhani et al., 2014) . Resolution of this argument is considered to be important for the study of developmental processes using these cell types as well as for their clinical application.
When iPSC colonies emerge, the reprogramming process is usually not complete. Thus, in early passages, iPSCs could show differences of gene expression and epigenetic status compared with ESCs that have been maintained for a longer period of time in vitro. Indeed, it has been demonstrated that continuous passaging of mouse iPSCs abrogates transcriptional, epigenetic and functional differences between iPSCs and ESCs, further approaching a homogeneous population (Polo et al., 2010) . Additionally, tetraploid complementation of mouse iPSCs produced normal pups, suggesting that selected fully reprogrammed iPSCs have bona fide naïve pluripotency, indistinguishable from that of ESCs (Boland et al., 2009; Kang et al., 2009; Zhao et al., 2009 ). Thus, these data suggest that transcription factor-mediated reprogramming can achieve the full spectrum of pluripotency in mice.
Regarding the similarities in transcriptional output and epigenetic modifications between human iPSCs and ESCs, conflicting results have been reported. Indeed, studies that used 2-6 ESC lines and 2-12 iPSC lines found notable differences in gene expression and/or DNA methylation between ESCs and iPSCs (Chin et al., 2009; Deng et al., 2009; Doi et al., 2009; Marchetto et al., 2009; Ghosh et al., 2010; Kim et al., 2011; Lister et al., 2011; Ohi et al., 2011) , whereas studies that used 20-36 ESC lines and 12-68 iPSC lines found ESCs and iPSCs to be fairly similar in terms of chromatin structure, gene expression and DNA methylation profiles (Guenther et al., 2010; Newman and Cooper, 2010; Bock et al., 2011) . Therefore, the number of cell lines analyzed might influence the conclusions regarding whether ESCs and iPSCs are equivalent. However, it has also been demonstrated that in human cells, certain reprogramming events, including X-chromosome reactivation and re-suppression of transiently activated genes, were incomplete in iPSCs at the early passages (Tomoda et al., 2012; Ohnuki et al., 2014) , indicating that the reprogramming process might take longer in human cells compared with murine cells. Thus, certain iPSC lines might be only partially re-programmed, and thus cannot be compared with ESCs. For example, Koyanagi-Aoi et al.
performed comparison analyses of gene expression, miRNA expression and DNA methylation between ten ESC lines and 39 iPSC lines (Koyanagi-Aoi et al., 2013) . Although they saw no clear differences between the two cell types, they did find that some iPSC lines exhibited distinct expression signatures that related to defects in differentiation. However, genes that were abundantly expressed in differentiation-defective iPSCs included many HERV-H-related genes, suggesting that these differentiation-defective iPSCs are partially reprogrammed cells. Therefore, we argue that mature iPSCs, which exclude incompletely reprogrammed clones, are probably indistinguishable from ESCs based on gene expression profiles and epigenetic status. However, because genetic background variations including single nucleotide polymorphisms affect PSC characteristics, a definitive comparison between cell lines derived from different sources is difficult.
Recently, human SCNT-ESCs were generated (Tachibana et al., 2013; Chung et al., 2014; Yamada et al., 2014) and a comparison of the gene expression profile, the epigenetic status and the genetic alterations was performed between isogenic human SCNT-ESCs and iPSCs derived from the same somatic cell cultures Ma et al., 2014) . Ma et al. concluded that iPSCs have inherent abnormalities because SCNT-ESCs are more similar to ESCs than iPSCs (Ma et al., 2014) . Although imprinting loss occurred in both SCNT-ESC and iPSC lines at similar frequencies, only in iPSCs did some imprinted genes, such as DIRAS3, MEG3 and PEG3, have aberrant DNA methylation status and defective XCI. By contrast, Johannesson et al. concluded that human SCNT-ESCs and iPSCs show no significant differences in gene expression, DNA methylation or frequency of de novo coding mutations .
Recent technologies have allowed the analysis of the expression profile of human pre-implantation embryos and ESCs at the singlecell level (Yan et al., 2013) and two recent papers have revealed significant differences in the global DNA methylation status of ESCs and blastocysts Smith et al., 2014 ). These studies demonstrate that human ESCs in a dish are not identical to embryos in their natural milieu. Hence, a satisfying description of proper human pluripotent stem cells is needed before we can determine whether factor-induced reprogramming causes abnormalities.
Conclusions
In this Review, we have summarized common features observed between transcription factor-induced reprogramming of differentiated somatic cells toward iPSCs and normal embryonic development (Fig. 4) . Although there are holistic differences between these opposite phenomena, including their kinetics, at the unicellular level and within a defined species, both processes involve similar mechanisms directing cell fate changes. Thus, we predict that a more detailed understanding of cell reprogramming will help us to understand human embryonic development.
In particular, understanding the mechanisms by which pluripotency is established and defining the naïve state of human pluripotency in vitro is a much sought after goal (Pera, 2014) . In the past few years, several strategies to create human naïve pluripotency have been proposed (Chan et al., 2013; Gafni et al., 2013; Takashima et al., 2014; Theunissen et al., 2014; Valamehr et al., 2014; Ware et al., 2014) and naïve human ESCs, which exhibited global DNA hypomethylation except on imprinted gene loci (a feature similar to that of pre-implantation embryos), were recently obtained using the inhibitors of MEK, GSK3 and protein kinase C (PKC) (Takashima et al., 2014) . These studies open the way to a deeper understanding of the naïve state of human pluripotency, which will bring a definitive end to the controversial comparison between murine and human cells and shed light on the mechanisms of reprogramming.
In this Review, we introduced the similarities and differences between transcription factor-induced reprogramming toward pluripotency and embryonic development. OSKM-mediated reprogramming requires reversing development, but not necessarily by simply going backwards along the differentiation process. Knowledge of developmental biology gives us hints as to the mechanisms of cell fate changes and determination that might also apply to the reprogramming process. However, if a novel approach for reprogramming of somatic cells is discovered, it might very well go through an entirely different route than the reversion of the developmental path (Fig. 1, broken arrow) .
